Alan F. Schatzberg

Psychiatry

965 High St
Palo Alto, CA 94301

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 175 publications

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

Journal: The American journal of psychiatry

Published: May 19, 2026

General Anesthesia and Discrete Components of Ketamine Neurophysiology.

General Anesthesia and Discrete Components of Ketamine Neurophysiology.

Journal: JAMA psychiatry

Published: April 08, 2026

Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.

Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.

Journal: The American journal of psychiatry

Published: March 18, 2026

Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy.

Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy.

Journal: World psychiatry : official journal of the World Psychiatric Association (WPA)

Published: January 15, 2026

Coding Inequities in Psychiatric Care: A Call to Align DSM/ICD With Chronic Disease Management.

Coding Inequities in Psychiatric Care: A Call to Align DSM/ICD With Chronic Disease Management.

Journal: The American journal of psychiatry

Published: November 05, 2025

Ketamine/esketamine treatment for resistant depression in children and adolescents: a PRISMA systematic review.

Ketamine/esketamine treatment for resistant depression in children and adolescents: a PRISMA systematic review.

Journal: European child & adolescent psychiatry

Published: October 09, 2025

Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.

Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.

Journal: The American journal of psychiatry

Published: October 01, 2025

Esketamine Treatment for Depression in Adults: Response to Price et al. and Canuso et al.

Esketamine Treatment for Depression in Adults: Response to Price et al. and Canuso et al.

Journal: The American journal of psychiatry

Published: October 01, 2025

Correction: Treatment of Refractory Bipolar Depression With Stereotactic Radiosurgery Targeting the Subgenual Cingulate Cortex.

Correction: Treatment of Refractory Bipolar Depression With Stereotactic Radiosurgery Targeting the Subgenual Cingulate Cortex.

Journal: Cureus

Published: September 08, 2025

Methodological considerations for interpreting ketamine-naltrexone trials in depression.

Methodological considerations for interpreting ketamine-naltrexone trials in depression.

Journal: The international journal of neuropsychopharmacology

Published: September 04, 2025

Comment on Buse et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 2025;48:2012-2020.

Comment on Buse et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 2025;48:2012-2020.

Journal: Diabetes care

Published: May 30, 2025

Bifunctional modulation of NMDA and opioid receptors in ketamine reinforcement and misuse: implications for substance use disorder treatment.

Bifunctional modulation of NMDA and opioid receptors in ketamine reinforcement and misuse: implications for substance use disorder treatment.

Journal: Biological psychiatry

Published: May 19, 2025

Showing 1-12 of 175

Last Updated: 09/26/2026